231 related articles for article (PubMed ID: 21266808)
1. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
Watanabe M; Nagai Y; Kinoshita K; Saito S; Kurashige J; Karashima R; Hirashima K; Sato N; Imamura Y; Hiyoshi Y; Baba Y; Iwagami S; Miyamoto Y; Iwatsuki M; Hayashi N; Baba H
Digestion; 2011; 83(3):146-52. PubMed ID: 21266808
[TBL] [Abstract][Full Text] [Related]
2. A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Shimakawa T; Naritaka Y; Asaka S; Isohata N; Yamaguchi K; Murayama M; Konno S; Katsube T; Ogawa K; Ide H
Anticancer Res; 2010 Jan; 30(1):221-6. PubMed ID: 20150639
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Osaka Y; Shinohara M; Hoshino S; Ogata T; Takagi Y; Tsuchida A; Aoki T
Anticancer Res; 2011 Feb; 31(2):633-8. PubMed ID: 21378349
[TBL] [Abstract][Full Text] [Related]
4. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
11. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
[TBL] [Abstract][Full Text] [Related]
12. [Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Katsumi C; Bamba T; Nakagawa S; Aizawa M; Matsuki A; Yabusaki H; Homma K
Gan To Kagaku Ryoho; 2017 Jan; 44(1):75-78. PubMed ID: 28174385
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer].
Minowa M; Kinoshita Y; Hasebe S; Ito T; Ogawa M; Takebayashi K; Ehara K; Ueno M; Udagawa H; Hayashi M
Gan To Kagaku Ryoho; 2011 Mar; 38(3):393-7. PubMed ID: 21403440
[TBL] [Abstract][Full Text] [Related]
14. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.
Overman MJ; Kazmi SM; Jhamb J; Lin E; Yao JC; Abbruzzese JL; Ho L; Ajani J; Phan A
Cancer; 2010 Mar; 116(6):1446-53. PubMed ID: 20108336
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
16. [Pathological Complete Response in a Case of Advanced Esophageal Cancer with Widespread Lymph Node Metastases Treated Using Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-FU(DCF therapy)].
Noro H; Hirao T; Takaichi S; Son C; Iwamoto K; Kono E; Yasumasa K; Mizuno H; Morimoto Y; Hatanaka N; Yamasaki Y
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2178-2180. PubMed ID: 28133261
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
Tamura S; Imano M; Takiuchi H; Kobayashi K; Imamoto H; Miki H; Goto Y; Aoki T; Peng YF; Tsujinaka T; Furukawa H;
Anticancer Res; 2012 Apr; 32(4):1403-8. PubMed ID: 22493377
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study.
Pasini F; de Manzoni G; Zanoni A; Grandinetti A; Capirci C; Pavarana M; Tomezzoli A; Rubello D; Cordiano C
Cancer; 2013 Mar; 119(5):939-45. PubMed ID: 23165781
[TBL] [Abstract][Full Text] [Related]
19. Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil.
Nakajima M; Muroi H; Kikuchi M; Takahashi M; Ihara K; Shida Y; Kurayama E; Ogata H; Yamaguchi S; Sasaki K; Sakai M; Sohda M; Miyazaki T; Kuwano H; Kato H
Anticancer Res; 2018 Feb; 38(2):911-918. PubMed ID: 29374720
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer.
Yamamoto K; Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Mori M; Doki Y
Anticancer Res; 2009 Oct; 29(10):4211-5. PubMed ID: 19846975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
